Marcia Eisenberg - Feb 21, 2025 Form 4 Insider Report for Singular Genomics Systems, Inc. (OMIC)

Role: Director
Signature: /s/ Dalen Meeter, Attorney-in-Fact
Stock symbol: OMIC
Transactions as of: Feb 21, 2025
Transactions value $: -$16,354
Form type: 4
Date filed: 2/25/2025, 08:04 PM
Previous filing: Jun 14, 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OMIC	Stock Option (Right to Buy)	Disposed to Issuer	$0	-4.93K	-100%	$0.00	0	Feb 21, 2025	Common Stock	4.93K	$22.41	Direct	F1, F2
transaction	OMIC	Stock Option (Right to Buy)	Disposed to Issuer	-$16.4K	-1.85K	-100%	$8.84	0	Feb 21, 2025	Common Stock	1.85K	$11.16	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Marcia Eisenberg is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.
F2	As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

Content

Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.